Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria
Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical trial, CBS-HCY-01, for OT-58, a modified recombinant enzyme therapy aimed at treating classical homocystinuria (HCU). This rare and debilitating metabolic disorder leads to severe cardiovascular, neurologic, skeletal, and ophthalmologic complications, and currently lacks effective treatment options. OT-58 […]